Multiple Myeloma Coverage from Every Angle
Advertisement
Advertisement

Ongoing CE Activities

A Multidisciplinary Approach to Individualized Patient Care – Multiple Myeloma
Recorded Presentations from the NCCN 2017 Nursing Forum: Advancing Oncology Nursing in Hematologic Malignancies
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
Autologous Stem Cell Transplantation in Multiple Myeloma: Who, When, and How?
CAR-T Cell Therapy for Blood Cancer Patients
Clinical Investigator Perspectives on Key Questions and Emerging Research in the Management of Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma
JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
Combined CAR-T Targeting Yields High Response Rate in Myeloma
NCCN 2018-2019 Case Manager and Medical Director Program: Diagnosis and Management of Hematologic Malignancies
From Quandary to Clarity in Relapsed/Refractory Multiple Myeloma: Optimizing Treatment and Empowering Patients
High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy
Insights on Individualizing Treatment of Patients with Multiple Myeloma
JADPRO CE: Updates in Multiple Myeloma
Multidisciplinary Care of Patients with Relapsed/Refractory Multiple Myeloma
Multiple Myeloma Update: Conversations with Oncology Investigators Bridging the Gap between Research and Patient Care, Issue 1, 2018
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2020
NCCN Oncology Case Manager and Medical Director Program: New Treatments for Metastatic Lung Cancer
NCCN Pharmacy Updates: Integrating New Treatment Options for Multiple Myeloma: Focus on Oral Therapies
Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma
Oncology Nursing Update, Lymphoma and Multiple Myeloma Edition, Issue 1, 2017
Proteasome Inhibitors in Multiple Myeloma
Recorded Presentations From the NCCN 2019 Annual Congress: Hematologic Malignancies™
Redefining Value Propositions and Managed Care Considerations in Multiple Myeloma
Relapsing/Refractory Multiple Myeloma in a High-Risk Patient: Efficacy With Monoclonal Antibody Therapy as Part of Triple Therapy
Role of Proteasome Inhibitor Therapy in a Patient with High-Risk Relapsing Multiple Myeloma
Shaping the Future of Myeloma Treatment
The Role of Maintenance Therapy in Multiple Myeloma
Treating Transplant-Ineligible Patients with MM


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.